Analgesia Nociception Index (ANI®) Module
for Root to be Previewed at the European Society of Anaesthesiology in
Geneva, SwitzerlandJune 3 – 5, 2017
IRVINE, Calif. & LILLE, France--(BUSINESS WIRE)--Jun. 1, 2017--
Masimo
(NASDAQ: MASI) and Mdoloris
Medical Systems announced today a Masimo Open Connect™ (MOC)
partnership for the Root® Open Architecture Patient
Monitoring and Connectivity Hub, in which Mdoloris is developing and
will commercialize their Analgesia Nociception Index (ANI®)
technology for Root.
This Smart News Release features multimedia. View the full release here:
http://www.businesswire.com/news/home/20170601005565/en/
Masimo’s unique approach to medical technology integration through MOC
partnerships is expected to address some major barriers to new
technology adoption in patient monitoring. Root’s open architecture and
built-in connectivity enable third-party companies to determine
themselves whether to pursue an integrated product. They can then
independently develop, obtain regulatory approvals, and commercialize
their own external MOC-9 module or Masimo Open Connect Control (MOC-CTM)
App for Root using Masimo’s MOC software development kit (SDK). Masimo’s
engineering team supports MOC partner development as needed and Masimo’s
commercial team helps increase awareness of the availability of MOC-9
modules and MOC-C Apps from MOC partners. In turn, MOC partners use
their existing distribution channels to sell their MOC-9 module or MOC-C
App to Masimo customers already using Root, as well as offering the
MOC-9 module or MOC-C App for Root to their potential customers as an
additional option to implement their technology.
Pain relief is a major concern of all developed countries while pain
assessment has historically been subjective, time-consuming due to its
manual nature, and intermittent. To address these limitations, Mdoloris
has developed ANI technology to provide an objective, noninvasive, and
continuous way to automatically monitor the pain level of patients. Use
of the ANI may help clinicians improve pain assessment and through it,
patient care and pain management with more objective and precise drug
administration.
“We are proud to announce our first MOC partnership and expect Root’s
advanced patient monitoring and versatile connectivity options will be
strengthened through MOC development and the addition of innovative new
technologies such as ANI from Mdoloris," said Joe Kiani, Founder and CEO
of Masimo. “We believe that Root with Masimo Open Connect can do for
patient monitoring what the PC did for computing: speed up the patient
monitoring innovation cycle, reduce the cost of patient monitoring, and
prolong the useful life of the equipment hospitals invest in.”
“We consider Masimo to be the most innovative company in the patient
monitoring space, so it is a pleasure to announce our MOC partnership.
We share Masimo’s vision of improving patient outcomes and reducing the
cost of care and believe Root offers a unique and compelling solution to
implement our ANI technology,” said Fabien Pagniez, Founder and CEO of
Mdoloris Medical Systems.
The ANI MOC-9 module for Root will be available for preview in the
Mdoloris exhibit booth at the European Society of Anaesthesiology in
Geneva, Switzerland, June 3 to 5, 2017.
ANI has not received 510(k) clearance and is not available for sale in
the United States.
@MasimoInnovates |
#Masimo
About Mdoloris Medical Systems
Mdoloris (www.mdoloris.com),
a medical devices manufacturer, was created in June 2010 out of 23 years
of academic research performed in Lille University hospital, France. It
has an international representation in more than 58 countries and a
scientific, technical and medical acknowledgement. Mdoloris has
developed so far three products, all able to continuously assess the
pain level of patients (The ANI technology for patients older than two
years old, the NIPE technology for neonates, the PTA technology for
pets). Its innovative technologies provide clinical added values for
clinicians that are not able to communicate with their patients in order
to personalize pain medications and avoid known side effects due to over
/ under dosage of such drugs.
About Masimo
Masimo (NASDAQ: MASI) is a global leader in innovative noninvasive
monitoring technologies. Our mission is to improve patient outcomes and
reduce the cost of care by taking noninvasive monitoring to new sites
and applications. In 1995, the company debuted Masimo SET®
Measure-through Motion and Low Perfusion™ pulse oximetry, which has been
shown in multiple studies to significantly reduce false alarms and
accurately monitor for true alarms. Masimo SET® has also been
shown to help clinicians reduce severe retinopathy of prematurity in
neonates,1 improve CCHD screening in newborns,2
and, when used for continuous monitoring with Masimo Patient SafetyNet™*
in post-surgical wards, reduce rapid response activations and costs.3,4,5
Masimo SET® is estimated to be used on more than 100 million
patients in leading hospitals and other healthcare settings around the
world,6 including 16 of the top 20 hospitals listed in the
2016-17 U.S. News and World Report Best Hospitals Honor Roll.7
In 2005, Masimo introduced rainbow® Pulse CO-Oximetry
technology, allowing noninvasive and continuous monitoring of blood
constituents that previously could only be measured invasively,
including total hemoglobin (SpHb®), oxygen content (SpOC™),
carboxyhemoglobin (SpCO®), methemoglobin (SpMet®),
and more recently, Pleth Variability Index (PVi®) and Oxygen
Reserve Index (ORi™), in addition to SpO2, pulse rate, and
perfusion index (PI). In 2014, Masimo introduced Root®, an
intuitive patient monitoring and connectivity platform with the Masimo
Open Connect™ (MOC-9™) interface, enabling other companies to augment
Root with new features and measurement capabilities. Masimo is also
taking an active leadership role in mHealth with products such as the
Radius-7™ wearable patient monitor, iSpO2® pulse
oximeter for smartphones, and the MightySat™ fingertip pulse oximeter.
Additional information about Masimo and its products may be found at www.masimo.com.
Published clinical studies on Masimo products can be found at http://www.masimo.com/cpub/clinical-evidence.htm.
*The use of the trademark Patient SafetyNet is under license from
University HealthSystem Consortium.
ORi has not received 510(k) clearance and is not available for sale in
the United States.
References
-
Castillo A et al. Prevention of Retinopathy of Prematurity in Preterm
Infants through Changes in Clinical Practice and SpO2
Technology. Acta Paediatr. 2011 Feb;100(2):188-92.
-
de-Wahl Granelli A et al. Impact of pulse oximetry screening on the
detection of duct dependent congenital heart disease: a Swedish
prospective screening study in 39,821 newborns. BMJ. 2009;338.
-
Taenzer AH et al. Impact of Pulse Oximetry Surveillance on Rescue
Events and Intensive Care Unit Transfers: A Before-And-After
Concurrence Study. Anesthesiology. 2010; 112(2):282-287.
-
Taenzer AH et al. Postoperative Monitoring – The Dartmouth Experience. Anesthesia
Patient Safety Foundation Newsletter. Spring-Summer 2012.
-
McGrath SP et al. Surveillance Monitoring Management for General Care
Units: Strategy, Design, and Implementation. The Joint Commission
Journal on Quality and Patient Safety. 2016 Jul;42(7):293-302.
-
Estimate: Masimo data on file.
- http://health.usnews.com/health-care/best-hospitals/articles/best-hospitals-honor-roll-and-overview.
Forward-Looking Statements
This press release includes forward-looking statements as defined in
Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934, in connection with the Private
Securities Litigation Reform Act of 1995. These forward-looking
statements include, among others, statements regarding the potential
effectiveness of Masimo Open Connect.These forward-looking
statements are based on current expectations about future events
affecting us and are subject to risks and uncertainties, all of which
are difficult to predict and many of which are beyond our control and
could cause our actual results to differ materially and adversely from
those expressed in our forward-looking statements as a result of various
risk factors, including, but not limited to: risks related to our
assumptions regarding the repeatability of clinical results; risks
related to our belief that Masimo's unique noninvasive measurement
technologies, including Masimo Open Connect, contribute to positive
clinical outcomes and patient safety; as well as other factors discussed
in the "Risk Factors" section of our most recent reports filed with the
Securities and Exchange Commission ("SEC"), which may be obtained for
free at the SEC's website at www.sec.gov.
Although we believe that the expectations reflected in our
forward-looking statements are reasonable, we do not know whether our
expectations will prove correct. All forward-looking statements included
in this press release are expressly qualified in their entirety by the
foregoing cautionary statements. You are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of
today's date. We do not undertake any obligation to update, amend or
clarify these statements or the "Risk Factors" contained in our most
recent reports filed with the SEC, whether as a result of new
information, future events or otherwise, except as may be required under
the applicable securities laws.
Potential MOC Partners Contact:
http://www.masimo.com/home/signal-extraction-pulse-oximetry/masimo-set-monitors/root/moc-9-web-form/
View source version on businesswire.com: http://www.businesswire.com/news/home/20170601005565/en/
Source: Masimo
Masimo
Evan Lamb, 949-396-3376
elamb@masimo.com
or
Mdoloris
Antoine
Szczypa
Antoine.szczypa@mdoloris.com